Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs

David R Deyle, Iram F. Khan, Gaoying Ren, Pei Rong Wang, Jordan Kho, Ulrike Schwarze, David W. Russell

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Osteogenesis imperfecta (OI) is caused by dominant mutations in the type I collagen genes. In principle, the skeletal abnormalities of OI could be treated by transplantation of patient-specific, bone-forming cells that no longer express the mutant gene. Here, we develop this approach by isolating mesenchymal cells from OI patients, inactivating their mutant collagen genes by adeno-associated virus (AAV)-mediated gene targeting, and deriving induced pluripotent stem cells (iPSCs) that were expanded and differentiated into mesenchymal stem cells (iMSCs). Gene-targeted iMSCs produced normal collagen and formed bone in vivo, but were less senescent and proliferated more than bone-derived MSCs. To generate iPSCs that would be more appropriate for clinical use, the reprogramming and selectable marker transgenes were removed by Cre recombinase. These results demonstrate that the combination of gene targeting and iPSC derivation can be used to produce potentially therapeutic cells from patients with genetic disease.

Original languageEnglish (US)
Pages (from-to)204-213
Number of pages10
JournalMolecular Therapy
Volume20
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Osteogenesis Imperfecta
Induced Pluripotent Stem Cells
Collagen
Bone and Bones
Gene Targeting
Mesenchymal Stromal Cells
Genes
Dependovirus
Inborn Genetic Diseases
Collagen Type I
Transgenes
Transplantation
Mutation
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Deyle, D. R., Khan, I. F., Ren, G., Wang, P. R., Kho, J., Schwarze, U., & Russell, D. W. (2012). Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs. Molecular Therapy, 20(1), 204-213. https://doi.org/10.1038/mt.2011.209

Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs. / Deyle, David R; Khan, Iram F.; Ren, Gaoying; Wang, Pei Rong; Kho, Jordan; Schwarze, Ulrike; Russell, David W.

In: Molecular Therapy, Vol. 20, No. 1, 01.2012, p. 204-213.

Research output: Contribution to journalArticle

Deyle, DR, Khan, IF, Ren, G, Wang, PR, Kho, J, Schwarze, U & Russell, DW 2012, 'Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs', Molecular Therapy, vol. 20, no. 1, pp. 204-213. https://doi.org/10.1038/mt.2011.209
Deyle, David R ; Khan, Iram F. ; Ren, Gaoying ; Wang, Pei Rong ; Kho, Jordan ; Schwarze, Ulrike ; Russell, David W. / Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs. In: Molecular Therapy. 2012 ; Vol. 20, No. 1. pp. 204-213.
@article{eaca3b9c2be64ee1a4de5e834c9b8d92,
title = "Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs",
abstract = "Osteogenesis imperfecta (OI) is caused by dominant mutations in the type I collagen genes. In principle, the skeletal abnormalities of OI could be treated by transplantation of patient-specific, bone-forming cells that no longer express the mutant gene. Here, we develop this approach by isolating mesenchymal cells from OI patients, inactivating their mutant collagen genes by adeno-associated virus (AAV)-mediated gene targeting, and deriving induced pluripotent stem cells (iPSCs) that were expanded and differentiated into mesenchymal stem cells (iMSCs). Gene-targeted iMSCs produced normal collagen and formed bone in vivo, but were less senescent and proliferated more than bone-derived MSCs. To generate iPSCs that would be more appropriate for clinical use, the reprogramming and selectable marker transgenes were removed by Cre recombinase. These results demonstrate that the combination of gene targeting and iPSC derivation can be used to produce potentially therapeutic cells from patients with genetic disease.",
author = "Deyle, {David R} and Khan, {Iram F.} and Gaoying Ren and Wang, {Pei Rong} and Jordan Kho and Ulrike Schwarze and Russell, {David W.}",
year = "2012",
month = "1",
doi = "10.1038/mt.2011.209",
language = "English (US)",
volume = "20",
pages = "204--213",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs

AU - Deyle, David R

AU - Khan, Iram F.

AU - Ren, Gaoying

AU - Wang, Pei Rong

AU - Kho, Jordan

AU - Schwarze, Ulrike

AU - Russell, David W.

PY - 2012/1

Y1 - 2012/1

N2 - Osteogenesis imperfecta (OI) is caused by dominant mutations in the type I collagen genes. In principle, the skeletal abnormalities of OI could be treated by transplantation of patient-specific, bone-forming cells that no longer express the mutant gene. Here, we develop this approach by isolating mesenchymal cells from OI patients, inactivating their mutant collagen genes by adeno-associated virus (AAV)-mediated gene targeting, and deriving induced pluripotent stem cells (iPSCs) that were expanded and differentiated into mesenchymal stem cells (iMSCs). Gene-targeted iMSCs produced normal collagen and formed bone in vivo, but were less senescent and proliferated more than bone-derived MSCs. To generate iPSCs that would be more appropriate for clinical use, the reprogramming and selectable marker transgenes were removed by Cre recombinase. These results demonstrate that the combination of gene targeting and iPSC derivation can be used to produce potentially therapeutic cells from patients with genetic disease.

AB - Osteogenesis imperfecta (OI) is caused by dominant mutations in the type I collagen genes. In principle, the skeletal abnormalities of OI could be treated by transplantation of patient-specific, bone-forming cells that no longer express the mutant gene. Here, we develop this approach by isolating mesenchymal cells from OI patients, inactivating their mutant collagen genes by adeno-associated virus (AAV)-mediated gene targeting, and deriving induced pluripotent stem cells (iPSCs) that were expanded and differentiated into mesenchymal stem cells (iMSCs). Gene-targeted iMSCs produced normal collagen and formed bone in vivo, but were less senescent and proliferated more than bone-derived MSCs. To generate iPSCs that would be more appropriate for clinical use, the reprogramming and selectable marker transgenes were removed by Cre recombinase. These results demonstrate that the combination of gene targeting and iPSC derivation can be used to produce potentially therapeutic cells from patients with genetic disease.

UR - http://www.scopus.com/inward/record.url?scp=84863011615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863011615&partnerID=8YFLogxK

U2 - 10.1038/mt.2011.209

DO - 10.1038/mt.2011.209

M3 - Article

C2 - 22031238

AN - SCOPUS:84863011615

VL - 20

SP - 204

EP - 213

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -